Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in cardiovascular mortality (RR) Median compared with usual care (moderate certainty).
1 finding from 1 review
Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in heart failure hospitalisation, first (RR) Range of compared with usual care (moderate certainty).
1 finding from 1 review
Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in hyperkalaemia Range of compared with usual care (moderate certainty).
1 finding from 1 review
All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).
1 finding from 1 review
Quality of life Range of · patients with chronic heart failure with preserved ejection fraction
1 finding from 1 review
no estimate extracted
118 participants
High
All‐cause mortality · Older adults, 50 years and older
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in all‐cause mortality compared with continuation (low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · Older adults, 50 years and older
It is very uncertain whether discontinuation by no treatment/placebo of antihypertensives changes myocardial infarction (fatal and nonfatal) compared with continuation (very low certainty).
1 finding from 1 review
Hospital admissions · Older adults, 50 years and older
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in hospitalisation compared with continuation (low certainty).
1 finding from 1 review
Stroke (fatal + nonfatal + TIA) · Older adults, 50 years and older
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in stroke (fatal + nonfatal + TIA) compared with continuation (low certainty).
1 finding from 1 review
Systolic blood pressure · Older adults, 50 years and older
1 finding from 1 review
Diastolic blood pressure · Older adults, 50 years and older
1 finding from 1 review
Adverse drug reactions and adverse drug withdrawal reactions (adverse reactions) · Older adults, 50 years and older
1 finding from 1 review
Falls ‐ not reported · Older adults, 50 years and older
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause death · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Doubling of SCr · people with diabetes and kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found